Literature DB >> 7512045

The effect of angiostatic steroids and beta-cyclodextrin tetradecasulfate on corneal neovascularization in the rat.

A D Proia1, A Hirakata, J S McInnes, M W Scroggs, I Parikh.   

Abstract

Folkman and coworkers have described angiostatic steroids that markedly inhibit neovascularization of the rabbit cornea when given topically with beta-cyclodextrin tetradecasulfate (beta-CD), yet have minimal or no glucocorticoid or mineralocorticoid activity. Our objective was to extend these observations to another species, the rat. We induced neovascularization by cauterizing rat corneas with silver nitrate/potassium nitrate; drugs were applied topically four times per day for 4 days in most experiments. Submicron sized emulsions of lipid-soluble dexamethasone and the angiostatic steroids 17 alpha-hydroxyprogesterone (1 or 10 mg ml-1) and cortexolone (1 or 10 mg ml-1) were prepared by lecithin encapsulation of drug microcrystals. The vehicle for water-soluble hydrocortisone 21-phosphate (HCP) +/- beta-CD (Molecusol; Pharmatec, Inc) was 10% Tween 20 in Tris-buffered 0.9% saline. Angiogenesis was significantly inhibited only by 1 mg ml-1 dexamethasone (-63.2% when compared with controls), 0.5 mg ml-1 HCP + 1 mg ml-1 beta-CD (-33.4%), and 1 mg ml-1 HCP (-40.2%). HCP (0.5 mg ml-1) or beta-CD (1 or 2 mg ml-1) alone had no significant effect on neovascularization; the inhibition by 1.0 mg ml-1 HCP was not potentiated by 2 mg ml-1 beta-CD. We also tested HCP and tetrahydro-S (TH-S) using 1.5% hydroxypropyl methylcellulose vehicle and beta-CD from Takeda Chemical Industries, Ltd., to simulate the procedure of Folkman and coworkers.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7512045     DOI: 10.1006/exer.1993.1177

Source DB:  PubMed          Journal:  Exp Eye Res        ISSN: 0014-4835            Impact factor:   3.467


  6 in total

1.  Pharmacologic uncoupling of angiogenesis and inflammation during initiation of pathological corneal neovascularization.

Authors:  Jeremy M Sivak; Allison C Ostriker; Amber Woolfenden; John Demirs; Rosemarie Cepeda; Debby Long; Karen Anderson; Bruce Jaffee
Journal:  J Biol Chem       Date:  2011-11-09       Impact factor: 5.157

2.  Trans-Tenon's retrobulbar triamcinolone infusion for small choroidal neovascularisation.

Authors:  A A Okada; T Wakabayashi; E Kojima; Y Asano; T Hida
Journal:  Br J Ophthalmol       Date:  2004-08       Impact factor: 4.638

3.  Inhibition of experimental corneal neovascularisation by bevacizumab (Avastin).

Authors:  Roberta P A Manzano; Gholam A Peyman; Palwasha Khan; Petros E Carvounis; Muhamet Kivilcim; Min Ren; Jonathan C Lake; Patricia Chévez-Barrios
Journal:  Br J Ophthalmol       Date:  2006-12-19       Impact factor: 4.638

4.  Role of protein tyrosine phosphorylation in rat corneal neovascularization.

Authors:  A Hayashi; K S Popovich; H C Kim; E de Juan
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1997-07       Impact factor: 3.117

5.  Corneal angiogenic privilege: angiogenic and antiangiogenic factors in corneal avascularity, vasculogenesis, and wound healing (an American Ophthalmological Society thesis).

Authors:  Dimitri T Azar
Journal:  Trans Am Ophthalmol Soc       Date:  2006

6.  Dexamethasone inhibits interleukin-1beta-induced corneal neovascularization: role of nuclear factor-kappaB-activated stromal cells in inflammatory angiogenesis.

Authors:  Shintaro Nakao; Yasuaki Hata; Muneki Miura; Kousuke Noda; Yusuke N Kimura; Shuhei Kawahara; Takeshi Kita; Toshio Hisatomi; Toru Nakazawa; Yiping Jin; M Reza Dana; Michihiko Kuwano; Mayumi Ono; Tatsuro Ishibashi; Ali Hafezi-Moghadam
Journal:  Am J Pathol       Date:  2007-08-09       Impact factor: 4.307

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.